Shaji Kumar, MD, Reviews PFS With Daratumumab-Containing Therapy in Frontline Myeloma

Video
Conference|European Hematology Association Congress (EHA)

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.

CancerNetwork® sat down with Shaji Kumar, MD, of the Mayo Clinic, at the 2021 European Hematology Association (EHA) Congress to talk about the statistically significant improvement in progression-free survival observed when daratumumab (Dazalex) was added to lenalidomide (Revlimid) and dexamethasone (D-Rd) versus the 2-drug combination alone in the phase 3 MAIA trial (NCT02252172).1 Kumar also mentions overall survival being consistent with all the subgroups of patients.

Transcript:

Previous reports of the MAIA study [published] in the New England Journal of Medicine had included the earlier data that showed the significant improvement in progression-free survival and the improved depth of response in the overall response rate with the 3-drug combination compared with the 2-drug combination. Now with longer follow up, we continue to see the significant difference in progression-free survival. In fact, at 16-months, the progression-free survival rate for the daratumumab combination was 52.5% compared with 28.7% for lenalidomide and dexamethasone, so [there was] almost a doubling of the 16-month PFS rate with the [D-Rd] combination.

The initial data that was seen has been confirmed by the longer follow up. And then additionally…overall survival improvement appears to be consistent across all the subgroups of patients, irrespective of the age, baseline renal function, [and International Staging System] stage. The impact of adding daratumumab was less evident in patients with high-risk disease. But again, as data matures, we’ll get a better sense of what this means because only a small proportion of patients are high risk.

References

1. Theirry F, Kumar S, Torben P, et al. Overall survival results with daratumumab, Lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. Presented at: 2021 European HematologyAssociation Annual Meeting; June 9-17, 2021; Virtual; Abstract LB1901. Accessed June 29, 2021. https://bit.ly/3hmf7l9

2. Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104-2115. doi:10.1056/NEJMoa1817249

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Related Content
Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma

Ashley Chan
June 8th 2025
Article

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

Ashley Chan
June 5th 2025
Article

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Ashling Wahner
June 5th 2025
Article

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 5th 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.